Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft-vs.-Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)
Transfer of Specific Cellular and Humoral Anti-Tumor Immunity After Stem Cell Transplant (SCT) by Vaccinating Stage IV Breast Cancer Patients With Her2/ Neu Targeted T Cells and Transferring Immune T Cells into the Patients After SCT
Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants.
Enhanced Immune Reconstitution Despite In Vivo Lympho-Depletion As Part Of Acute Graft Vs Host Disease aGVHD Prophylaxis In Unrelated Hematopoietic Stem Cell Transplants UHSCT
Reviewing The Status Of Backup Hematopoietic Stem Cells (HSC) Banking For Multiple Myeloma (MM) Patients Who Are Eligible For Autologous Hematopoietic Stem Cells Transplant (AHSCT) In This Poor Economy
Aprepitant (AP) For Prevention Of Nausea And Vomiting Secondary To High-Dose Cyclophosphamide (Cy) Administered To Patients Undergoing Autologous (A) Peripheral Blood Progenitor Cell (Pbpc) Mobilization: Final Results Of A Phase Ii Trial
Primed And Boosted Anti-Breast Cancer Tumor Immunity After Autologous Peripheral Blood Stem Cell Transplant (PBSCT): In Vivo Priming With T Cells Armed With Anti-CD3 X anti-Her2/neu Bispecific Antibody (Her2Bi) Pre PBSCT And Boosting After PBSCT With Activated T Cells (ATC)
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
